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The Journal of Nutrition
Biochemical, Molecular, and Genetic Mechanisms
A Nanoparticulate Ferritin-Core Mimetic Is Well
Taken Up by HuTu 80 Duodenal Cells and Its
Absorption in Mice Is Regulated by Body Iron1,2
Gladys O Latunde-Dada,3* Dora IA Pereira,4 Bethan Tempest,3 Hibah Ilyas,3 Angela C Flynn,3
Mohamad F Aslam,4 Robert J Simpson,3 and Jonathan J Powell4
3Diabetes and Nutritional Sciences Division, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom;
and 4Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, Cambridge, United Kingdom
Abstract
Background: Iron (Fe) deficiency anemia remains the largest nutritional deficiency disorder worldwide. How the gut
acquires iron from nano Fe(III), especially at the apical surface, is incompletely understood.
Objective:We developed a novel Fe supplement consisting of nanoparticulate tartrate-modified Fe(III) poly oxo-hydroxide
[here termed nano Fe(III)], which mimics the Fe oxide core of ferritin and effectively treats iron deficiency anemia in rats.
Methods: We determined transfer to the systemic circulation of nano Fe(III) in iron-deficient and iron-sufficient outbread Swiss
mouse strain (CD1) mice with use of 59Fe-labeled material. Iron deficiency was induced before starting the Fe-supplementation
periodthroughreductionofFeconcentrations in the rodentdiet.Acontrolgroupof iron-sufficientmicewere fedadietwithadequate
Feconcentrations throughout thestudy.Furthermore,weconductedahemoglobin repletionstudy inwhich iron-deficientCD1mice
werefedfor7dadietsupplementedwith ferroussulfate (FeSO4)ornanoFe(III).Finally,wefurtherprobedthemechanismofcellular
acquisitionof nanoFe(III) by assessing ferritin formation, as ameasureof Feuptakeandutilization, inHuTu80duodenal cancer cells
with targeted inhibition of divalent metal transporter 1 (DMT1) and duodenal cytochrome b (DCYTB) before exposure to the
supplemented iron sources. Differences in gene expression were assessed by quantitative polymerase chain reaction.
Results: Absorption (means6 SEMs) of nano Fe(III) was significantly increased in iron-deficient mice (586 19%) compared to
iron-sufficient mice (18 6 17%) (P = 0.0001). Supplementation of the diet with nano Fe(III) or FeSO4 significantly increased
hemoglobin concentrations in iron-deficient mice (170 6 20 g/L, P = 0.01 and 180 6 20 g/L, P = 0.002, respectively). Hepatic
hepcidin mRNA expression reflected the nonheme-iron concentrations of the liver and was also comparable for both nano
Fe(III)– and FeSO4-supplemented groups, as were iron concentrations in the spleen and duodenum. Silencing of the solute
carrier family 11 (proton-coupled divalent metal ion transporter), member 2 (Slc11a2 ) gene (DMT1) significantly inhibited ferritin
formation from FeSO4 (P = 0.005) but had no effect on uptake and utilization of nano Fe(III). Inhibiting DCYTB with an antibody
also had no effect on uptake and utilization of nano Fe(III) but significantly inhibited ferritin formation from ferric nitrilotriacetate
chelate (Fe-NTA) (P = 0.04). Similarly, cellular ferritin formation from nano Fe(III) was unaffected by the Fe(II) chelator ferrozine,
which significantly inhibited uptake and utilization from FeSO4 (P = 0.009) and Fe-NTA (P = 0.005).
Conclusions:Our data strongly support direct nano Fe(III) uptake by enterocytes as an efficient mechanism of dietary iron
acquisition, which may complement the known Fe(II)/DMT1 uptake pathway. J Nutr 2014;144:1896–902.
Keywords: cellular uptake, iron absorption, iron deficiency anemia, iron supplementation, tartrate-modified Fe(III)
poly oxo-hydroxide
Introduction
Iron deficiency and iron deficiency anemia (IDA)5 are nutritional
disorders afflicting a substantial proportion of the worlds popula-
tion (1). These problems are most prevalent among vulnerable
infants, adolescent girls, pregnant women, and the elderly in both
developed and developing countries. Aside from the high iron
demand posed by increased physiologic requirements of growth
2 Author disclosures: GO Latunde-Dada, B Tempest, H Ilyas, AC Flynn, MF
Aslam, and RJ Simpson, no conflicts of interest. DIA Pereira and JJ Powell wish
to note that they are inventors on a patent detailing novel Fe(III) poly
oxo-hydroxide structures [Powell J, Bruggraber S, Faria N, Pereira D, inventors.
Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes
for their preparation (WO/2008/096130)], as described herein, which may have
further potential as commercial dietary supplements.
1 Supported by Kings College London (Diabetes and Nutritional Sciences
Division) and the U.K. Medical Research Council (U105960399). This is an
open access article distributed under the CC-BY license (http://creativecommons.
org/licenses/by/3.0/).
* To whom correspondence should be addressed. E-mail: yemisi.latunde-dada@
kcl.ac.uk.
1896 Manuscript received August 11, 2014. Initial review completed August 20, 2014. Revision accepted September 25, 2014.
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and reproduction, IDA is further accentuated by inadequate dietary
iron intake and poor iron bioavailability from food sources (2).
Debilitating effects of IDA on cognition, work performance,
and pregnancy outcomes have been reported (3, 4). The types
of iron compounds that are used for food fortification and/or
supplementation include simple Fe(II) salts (e.g., ferrous sulfate,
ferrous fumarate, ferrous gluconate); Fe(III) minerals/salts (e.g.,
ferric pyrophosphate, ferric ammonium citrate); Fe(III) che-
lates (e.g., sodium ferric EDTA, ferric citrate); and elemental Fe
powders (e.g., electrolytic iron, carbonyl iron). Simple Fe(II)
salts remain the oral iron compounds of choice (5, 6) despite
their well-recognized toxicity, which leads to gastrointestinal
side effects, compromised compliance, and additional health-
care costs (7–10). Moreover, current iron supplements might
induce DNA damage in the gastrointestinal tract by generating
reactive oxygen species through the Fenton reaction (11–13).
Another possible mechanism contributing to gastrointestinal
side effects is through iron-induced changes to the composition
of the colonic microflora (13–15). Finally, there are substantial
concerns that soluble Fe(III) chelates may directly increase tumor
burden in colorectal carcinogenesis, despite not being active in
redox cycling (16, 17).
We developed a nano particulate ligand-modified Fe(III) poly
oxo-hydroxide [i.e., tartrate-modified ferrihydrite, here termed
nano Fe(III)] that mimics the ferrihydrite core of ferritin and that
may find use in the prophylactic and therapeutic management of
IDA (18). Moreover, nano Fe(III) resembles the iron species
naturally formed in the intestinal lumen during digestion of die-
tary nonheme iron (19). We aimed to investigate the follow-
ing: 1) the impact of body iron status on iron absorption from
nano Fe(III) in outbread Swiss mouse strain (CD1) mice, which
are widely used in studies of iron metabolism (20–23); 2) the
efficacy of nano Fe(III) in treating iron deficiency anemia in
comparison with gold standard oral ferrous sulfate in the same
mouse model; and 3) the use of small interfering RNA (siRNA),
antibodies, and iron chelation to provide novel insights into the
acquisition of nano iron (III) by a duodenal epithelial cell line
(HuTu 80).
Methods
Fe(II) sulfate heptahydrate (FeSO4) and ferric ammonium citrate (FAC)
were purchased from Sigma-Aldrich. Fe(III) nitrilotriacetate chelate
[Fe(III)-NTA] was produced by mixing a solution of Fe(III) chloride (10
mmol/L) with a NTA solution to achieve a molar ratio of Fe:NTA of
1:2. FeSO4-ascorbate was prepared by mixing FeSO4 and ascorbic acid
in a molar ratio of 1:1 and [Fe] = 20 mmol/L. Ligand-modified Fe(III)
poly oxo-hydroxide, here referred to as nano Fe(III), was produced
following the protocol described by Powell et al. (18). Briefly, an acidic
concentrated stock solution of Fe(III) chloride was added to a solution
containing adipic and tartaric acids to obtain a final iron concentration
of 40 mmol/L and a molar ratio of Fe:adipic:tartaric = 2:1:1. The initial
pH of the mixture was <2.0, and the iron was fully solubilized as
determined by ultrafiltration (Mr 3000 molecular weight cut-off;
10,000 3 g, 10 min). The pH was then slowly increased by drop-wise
addition of a concentrated solution of NaOH with constant agitation
until approximately pH 7.4. The entire mixture was then oven-dried at
45C for a minimum of 24 h.
Animal studies
CD1 strain male mice (Charles Rivers) were used for the studies andwere
3 wk of age when weaned onto the test diets. Mice were housed in a
light- and temperature-controlled room with ad libitum access to
standard pellet diet and water. Animal care and all procedures were
conducted in accordance with methods approved by the United Kingdom
Animals (Scientific Procedures) Act 1986.
Hemoglobin repletion study. Twelve male CD1 mice (3 wk of age)
were made Fe deficient through use of a low-iron diet of;3-mg Fe/Kg diet
based on the modified AIN-76A purified rodent diet (24) (TD.80396;
Harlan Teklad) for 3 wk (i.e., until they were 6 wk of age). Four mice were
also placed on a normal iron-sufficient diet (48-mg Fe/Kg diet) (TD.80394;
Harlan Teklad) to serve as control. The diets were of identical composition
except that the iron-sufficient diet contained iron added as ferric citrate.
After this, blood was withdrawn from the tails to determine the initial Hb
concentrations of the mice. The Fe-deficient mice were then divided into 3
treatment groups based on similar Hb concentrations. These 12 mice were
maintained on the low-Fe diet in groups of 4, of which 1 group did not
receive any iron supplementation (low-iron diet); the 2 other groups were
gavaged daily with 150-mg Fe as nano Fe(III) compound or FeSO4 for 7 d
(until mice were 7 wk of age). After the 7 d, mice were weighed, anes-
thetized, and blood samples were taken for Hb and serum iron determi-
nations. The mice were then killed by isoflurane anesthesia followed by
neck dislocation, and the spleen, duodenum, kidney, and liver samples
were excised, snap frozen in liquid nitrogen, and stored at 280C until
further analysis.
59Fe absorption study. Iron absorption was measured in control iron-
sufficient mice (fed an iron-sufficient diet for 3 wk, i.e., mice were 6 wk
of age) and in iron-deficient mice (low-iron diet for 3 wk) that were feed-
deprived for ;16 h before given a test dose containing 20 mmol/L Fe as
nano 59Fe(III) or 59FeSO4-ascorbate. The test doses (100 mL) were
administered by oral gavage into the stomach (112 mg Fe). Mice were left
for 4 h (25) with free access to drinking water until they were killed and
tissue was collected as described by Simpson and Peters (26). Total
unabsorbed radioiron was defined as the sum of the amounts of radio-
iron in duodenal washes, and jejunum, ileum, and colonic tissue. All
values are expressed as a percentage of administered dose.
Cell studies
Duodenal HuTu 80 cells (a human epithelial adenocarcinoma adherent
cell line) were obtained from the American Type Culture Collection.
HuTu 80 cells do not differentiate with enterocyte-like properties such as
Caco-2 cells or form a polarized monolayer, but their siRNA transfection
efficiency is less variable. Cells were cultured in DMEM (Life Technol-
ogies) supplemented with 10% fetal calf serum (Sigma-Aldrich) and with
100-kU/L penicillin and 100-mg/L streptomycin. Cells were maintained
at 37C in an atmosphere of 5% CO2 and 95% air at a relative humidity
of;95%. Cells were passaged at 70% confluence with use of GibcoVersene
Solution (Life Technologies).
siRNA transfection. Small interfering RNA oligonucleotides were
purchased from Invitrogen Life Technologies. Cells were transfected
with 10 nM of either the Silencer Select Negative Control No.
1 (4390843, scramble) or Silencer Select siRNA targeting Slc11a2
(S9708). HuTu 80 cells at 50% confluence (24-h postseeding) were
transfected with siRNAs with use of RiboCellin transfection reagent
(BioCell Challenge), following protocols provided by the manufacturer.
Transfected cells were assayed after 72 h for divalent metal transporter 1
(DMT1) mRNA expression by qRT-PCR and for iron uptake as detailed
below. Antibody inhibition, targeting duodenal cytochrome b (DCYTB)
(cytochrome b reductase 1 polyclonal; Novus Biologicals) in HuTu 80 cells,
was carried out with use of ImmunoCellin live cells antibody transfection
reagent (BioCell Challenge) according to manufacturer protocols.
Iron uptake. To avoid aggregation/agglomeration of the nano Fe(III),
the medium used for cellular uptake consisted of a balanced salt solution
containing 130-mmol/L NaCl, 10-mmol/L KCl, 1-mmol/L MgSO4,
5-mmol/L glucose, and 1-mmol/L CaCl2 in 10-mmol/L PIPES buffer (pH
6.5) (27). Unless otherwise stated, the iron concentration was 10 mmol/L.
5 Abbreviations used: CD1, outbread Swiss mouse strain; DCYTB, duodenal
cytochrome b; DMT1, divalent metal transporter 1; FAC, ferric ammonium
citrate; Fe-NTA, ferric nitrilotriacetate chelate; FeSO4, ferrous sulfate; Hamp1,
hepcidin antimicrobial peptide 1; IDA, iron deficiency anemia; Rpl19, mouse
ribosomal protein L19; siRNA, small interfering RNA; Slc11a2, solute carrier
family 11 (proton-coupled divalent metal ion transporter), member 2.
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Confluent HuTu 80 cells were exposed to serum-freeDMEM for 4 h before
iron uptake studies as described by Pereira et al. (19). Cells were then
incubated for 1 h with 50- or 100-mmol/L [Fe] as nano Fe(III), FeSO4,
Fe-NTA, or FAC in balanced salt solution, plus 23 h in fresh non-
supplemented DMEM. To investigate the effect of ferrozine (1 mmol/L) or
zinc (50 mmol/L as ZnSO4) on cellular ferritin formation from nano Fe(III),
FeSO4, Fe-NTA, or FAC, cells were co-incubatedwith 10-mmol/L Fe and the
chemical inhibitor for 1 h followed by 23 h in fresh nonsupplemented
DMEM. The cell lysates were collected and used for ferritin and protein
analysis as previously described (19). Experiments were carried out in
triplicate and data expressed as nanogram ferritin per milligram cell protein.
Analysis
Hematology. Hemoglobin concentrations were calculated from the
change in optical density at 540 nm, after the addition of 5 mL of whole-
blood to Drabkins reagent (Sigma-Aldrich) and centrifugation (Heraeus
Biofuge Pico) at 16,060 3 g for 5 min.
Tissue nonheme iron. Tissue samples were weighed and homoge-
nized (1:5 wt:vol) in 0.15-mol/L NaCl in 10-mmol/L NaOH-Hepes
buffer (pH 7.0) with use of a 1-mL glass dounce homogenizer
(Wheaton Scientific). An aliquot of the homogenate was then analyzed
for nonheme-iron content with use of the ferrozine-based colorimetric
assay developed by Simpson and Peters (27). The iron values were
expressed as either content (mmol Fe/organ) or concentration (nmol Fe/
mg wet weight).
Real-Time PCR. Total RNAwas extracted from tissue samples through
use of TRIZOL reagent (Invitrogen) according to the manufacturers
instructions. To determine hepcidin antimicrobial peptide 1 (Hamp1)-
expression, quantitative RT-PCR was carried out with use of an ABI
Prism 7000 detection system (Applied Biosystems) in a 2-step protocol
with Roche Universal primers and probes. Quantitative measurement of
each gene was normalized to the threshold cycle value for mouse
ribosomal protein L19 (Rpl19).
Sequences of primers used are as follows (5#-3#):
Rpl19, forward CTCGTTGCCGGAAAAACA
Rpl19, reverse TCATCCAGGTCACCTTCTCA
Mouse Hamp1, forward AGAAAGCAGGGCAGACATTG
Mouse Hamp1, reverse CACTGGGAATTGTTACAGCATT
For the siRNA cell transfection experiments, Slc11a2 (DMT1) ex-
pression was determined with use of TaqMan Gene Expression Assay
Master Mix (Applied Biosystems), according to the manufacturers pro-
tocol, on an Applied Biosystems 7500 fast real-time PCR system using
probe ID:Hs00167206_m1 (5#-3#TGTGTTCTACTTGGGTTGGCAATGT).
Expression was relative to the 18S ribosomal RNA (18S) housekeeping
gene, and the percent knockdown was calculated with use of the DDCq
method.
Ferritin ELISA assay in cell lysates. The Spectro Ferritin MT ELISA
kit (ATI Atlas) was used to determine cellular ferritin content as de-
scribed in the manufacturers protocol. Cellular protein concentration
was determined according to Bio-Rad assay protocol (Bio-Rad Labora-
tories). Experiments were carried out in triplicates, and data are expressed
as nanogram ferritin per milligram protein.
Statistical analysis
Unless otherwise indicated, values are means6 SEMs, with the number
of independent experiments given in the figure legends. One-factor
ANOVA with the Tukeys test for multiple comparisons was used to
compare means for hemoglobin concentrations, Hamp1-expression,
and tissue (i.e., hepatic, splenic, duodenal) iron concentrations
between the different diet groups. In the mouse study, 2-factor
ANOVA was used to test the main effects and the interaction between
radioiron in each body compartment and iron status (i.e., Fe-deficient
and Fe-sufficient). Tukeys post hoc test was used to determine the
significant differences between radioiron absorption for nano Fe(III)
and FeSO4 in Fe-sufficient vs. Fe-deficient mice for each body
compartment. In the cellular assays, 2-factor ANOVA was used to
test the main effects and the interaction between the iron compound
FIGURE 1 In vivo bioavailability of nano Fe(III) and FeSO4 in male CD1 mice. Effect of iron status on the absorption of nano Fe(III) (A) or FeSO4
(B) in mice after oral gavage with 59Fe-labeled material. Box and whisker plots show median, minimum, and maximum (n = 6 per group). All
values are expressed as percentage of dose (i.e., the radio iron that has left the stomach). *Different from the Fe-sufficient control within each
body compartment, P , 0.05 (2-factor ANOVA). Hemoglobin concentrations (C) and Hamp1mRNA expression (D) of mice after 7-d feeding with
test diets supplemented with nano Fe(III) or FeSO4. Concentrations in control mice maintained in the Fe-sufficient or the Fe-deficient diets
throughout the study are also shown. Box and whisker plots show median, minimum, and maximum (n = 3 in the Fe-deficient group; n = 4 in
each of the other groups). Labeled means without a common letter differ, P, 0.05 (1-factor ANOVA). CD1, outbread Swiss mouse strain; FeSO4,
ferrous sulfate; Hamp1, hepcidin antimicrobial peptide 1.
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and the experimental treatments. Tukeys post hoc test was used to
determine significant differences in ferritin formation between the different
iron compounds in the different experimental conditions. Specific
comparisons were the following: ferritin formation for each compound
between the 2 Fe concentrations, ferritin formation for each compound
with and without the inhibitory factor (namely ferrozine, zinc, DCYTB
antibody, and Slc11a2 siRNA), and ferritin formation under each
experimental condition (i.e., Fe concentration and absence or presence of
the inhibitory factor) between the different iron compounds.
Differences were considered statistically significant at P < 0.05. All
statistical analyses were performed with use of GraphPad Prism 6.02 for
Windows (GraphPad Software).
Results
In vivo absorption of nano Fe(III) after gavage. First we were
interested in assessing impact of systemic iron status on iron
absorption of nano Fe(III). Hence, we compared iron absorption
4 h after gavage with a single dose of 59Fe- labeled FeSO4 or nano
Fe(III) in iron-deficient and iron-sufficient mice (Figure 1A, B). As
expected, iron absorption beyond gut uptake (i.e., systemic
transfer) was significantly lower (P < 0.0001) in iron-sufficient
mice than iron-deficient mice for FeSO4 (Figure 1B). There was
also significantly higher systemic transfer of iron from nano Fe(III)
in iron-deficient mice than iron-sufficient mice (P < 0.0001), but
the iron retained in the duodenal tissue was not significantly
different (Figure 1A). Iron retained in the jejunum, ileum, or colon
would normally be considered as unabsorbed iron (i.e., in transit).
Indeed, almost all of the unabsorbed iron from nano Fe(III) in
iron-sufficient mice could be accounted for in the ileal and colonic
samples (Figure 1A). Over the 4-h period, 49 6 17% of the
gavaged iron was transferred systemically for nano Fe(III) vs.
70 6 11% for ferrous sulfate (P = 0.03), although absolute com-
parisons in absorption are not easy because of likely differences in
kinetics of uptake as observed in humans (28).
In vivo bioavailability of nano Fe(III) in a feeding study.
Next we considered efficacy at repleting hemoglobin concentra-
tions of nano Fe(III) vs. FeSO4 after diet-induced iron deficiency.
Mice fed a diet low in Fe (Fe-deficient group) for 4 wk showed
significantly lower blood hemoglobin concentrations than con-
trol mice kept on the iron-sufficient diet (Fe-sufficient group)
throughout the study (P = 0.0007, Figure 1C). Supplementation
of the Fe-deficient diet with either nano Fe(III) or FeSO4 for 7 d
significantly increased hemoglobin concentrations in compari-
son with mice fed the Fe-deficient diet throughout the study (P =
0.01 and 0.002, respectively, Figure 1C). Hamp1 mRNA ex-
pression tended to be lower (P = 0.1) in Fe-deficient mice than
Fe-sufficient mice (Figure 1D). Mice fed the diets supplemented
with either nano Fe(III) or FeSO4 had hepatic Hamp1 mRNA
concentrations similar to control Fe-sufficient mice (P $ 0.6,
Figure 1D). There were no significant differences among the diet
groups in food intake or body weight throughout the study (data
not shown).
Tissue iron distribution. Feeding the Fe-deficient diet for 4 wk
reduced the nonheme-Fe concentration in the spleen (P = 0.003)
and tended to reduce it in the liver (P = 0.07) of Fe-deficient mice
compared with Fe-sufficient mice (Figure 2). The concentration
in the duodenum did not differ among groups. Final hepatic and
duodenal nonheme-Fe concentrations did not differ after 7 d of
iron supplementation in the test diets with either nano Fe(III) or
FeSO4 (Figure 2), and this was reflected by similar concentrations
of Hamp1 mRNA in the 2 Fe-supplemented groups (Figure 1D).
Nonheme-Fe concentrations in the spleen were still significantly
lower than those in Fe-sufficient control mice for both nano
Fe(III)- (P = 0.004) and FeSO4-supplemented (P = 0.008) groups
and for the group maintained on the Fe-deficient diet throughout
the study (P = 0.003) (Figure 2B).
Iron uptake mechanism in HuTu 80 cells. Ferritin formation
by HuTu 80 cells was used to assess cellular uptake and uti-
lization from nano Fe(III) in comparison to FeSO4, Fe-NTA,
or FAC. Ferritin formation after 1 h of exposure to 50- or
100-mmol/L Fe increased with dose for all compounds investi-
gated, and this was significant for nano Fe(III) (P < 0.0001),
FeSO4 (P = 0.0009), and Fe-NTA (P = 0.002) (Figure 3A). There
was no difference in Fe utilization after exposure of cells to nano
Fe(III) or FeSO4, but Fe utilization after Fe-NTA or FAC was
significantly lower (P# 0.02) (Figure 3A). In contrast to soluble
Fe(III) (Fe-NTA), cellular uptake and utilization of nano Fe(III)
by HuTu cells did not require prior reduction of Fe(III) to Fe(II)
as shown by Fe(II)-chelation with ferrozine and by DCYTB
antibody inhibition studies (Figure 3B, D). We also used an
excess of Zn (5:1), and siRNA targeting Slc11a2, to probe the
involvement of DMT1 on the apical uptake of iron from FeSO4
FIGURE 2 Tissue Fe distribution in male CD1 mice after supplemen-
tation with nano Fe(III) and FeSO4. Nonheme-iron concentrations in the
liver (A), spleen (B), and duodenum (C) of mice after 7-d feeding with
test diets supplemented with nano Fe(III) or FeSO4. Concentrations in
control mice maintained in the Fe-sufficient or the Fe-deficient diets
throughout the study are also shown. Box and whisker plots show
median, minimum, and maximum (n = 3 in the Fe-deficient group; n = 4
in each of the other groups). Labeled means without a common letter
differ, P , 0.05 (1-factor ANOVA). FeSO4, ferrous sulfate.
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and nano Fe(III) in HuTu cells. In contrast to findings with
FeSO4 (P = 0.02 with Zn and P = 0.005 with siRNA), there were
no significant differences in ferritin formation after nano Fe(III)
with or without Zn or siRNA transfection to inhibit DMT1, i.e.,
apical uptake of iron from nano Fe(III) in these cells was in-
dependent of DMT1 (Figure 3C, E). Calculations from qPCR
data with use of the DDCq method showed 87% knockdown
of DMT1 when cells were treated with the siRNA targeting
Slc11a2 [normalized to 18S housekeeping gene (Figure 3F)].
Discussion
Food iron fortification and the use of iron supplements are
approaches that have been adopted by several countries to try to
combat iron deficiency and IDA and improve iron nutrition (23,
24). Inexpensive simple ferrous salts continue to be the standard
for oral iron supplementation and fortification despite the many
concerns associated with gastrointestinal tolerability and toxic-
ity (5, 6, 11, 29). This is because alternative forms of oral iron,
that are currently in use or are being developed, may have benefit
in terms of improved tolerance but not demonstrably so in
safety, and are mostly expensive (30, 31). Thus, even if they are
well absorbed, they are often labile in the gut lumen or at the
mucosal surface and available for bacterial uptake (13, 15, 32)
or for the generation of toxic reactive oxygen species with po-
tential detrimental effects (12, 13). Chelated iron is a particular
concern with its effects on amplification of colon cancer risk
(16, 17).
We are attempting to address the unmet clinical need for an
economical, effective, safe, and tolerated form of oral iron that
will correct IDA without side effects. To meet this challenge we
have developed a mimetic of the form of iron that occurs
naturally in the gut lumen upon digestion of nonheme-food iron.
This synthetic mimetic is a nano particulate tartrate-modified
Fe(III) poly oxo-hydroxide [termed here nano Fe(III)]; it is
bioavailable in humans (28) and efficacious at treating IDA in
rats (18). We have also shown in a mouse model that systemic
transfer of iron, derived from nano Fe(III), is ferroportin-
mediated (33). With the studies reported herein we add to this
knowledge and now show that, in mice, the absorption of nano
Fe(III) is regulated by systemic iron status (Figure 1) similarly to
soluble iron species (34–36). Importantly, to our knowledge, this
is the first report to show that nano Fe(III) is under normal iron
homeostasis in wild-type mice of varying Fe status. Moreover,
we provide some evidence of a further homeostatic step for iron
absorption from nano Fe(III) in vivo because enterocyte reten-
tion of iron, in iron-sufficient mice, was much lower after dosing
with nano Fe(III) than ferrous sulfate (Figure 1). Finally, we have
validated in the anemic CD1 mouse, which is commonly used in
iron metabolism studies, that nano Fe(III) is very similar in ef-
ficacy to the clinical standard ferrous sulfate for restoring hemo-
globin concentrations (Figure 1).
Tissue nonheme-iron concentrations in the liver and spleen of
mice were reduced after 3 wk of dietary-induced iron deficiency
(Figure 2) showing that these mice had indeed low iron status
(37). Mean hepatic, splenic, and duodenal nonheme-iron
FIGURE 3 Uptake and utilization of nano Fe(III) in HuTu 80 cells. (A) Cellular ferritin concentrations in HuTu 80 cells after exposure to 50- or
100-mmol/L [Fe] as nano Fe(III), FeSO4, Fe-NTA, or FAC. Baseline ferritin concentrations in control cells incubated only with the BSS vehicle (gray
bar) were ;26 ng/mg cell protein and are shown for reference. Effect of ferrozine (B) or zinc (C) on cellular ferritin formation from nano Fe(III),
FeSO4, Fe-NTA, or FAC. Effect of Ab inhibition targeting DCYTB (D) or siRNA targeting Slc11a2 (E) on nano Fe(III) uptake and utilization in HuTu
80 cells. (A–E) Values are means 6 SDs of 3 independent experiments (each experiment with 3 replicate wells). Means for each experimental
condition (i.e., [Fe] concentration in A or inhibitor/knockdown treatment in B–E) without a common letter differ, P , 0.05. *Different from the
corresponding control (closed bars) for each iron compound (2-factor ANOVA). (F) Relative DMT1 gene expression (Slc11a2) from qPCR data with
18S ribosomal RNA as the endogenous housekeeping gene. Values are the mean of 2 replicates in the same experiment and percentage
knockdown is shown relative to the nontargeting scramble. Ab, antibody; BSS, balanced salt solution; DCYTB, duodenal cytochrome b; DMT1,
divalent metal transporter 1; FAC, ferric ammonium citrate; Fe-NTA, ferric nitrilotriacetate chelate; FeSO4, ferrous sulfate; siRNA, small
interfering RNA; Slc11a2, solute carrier family 11 (proton-coupled divalent metal ion transporter), member 2.
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concentrations were similar after supplementation with nano
Fe(III) or FeSO4 (Figure 2). After the 7-d supplementation period
with nano Fe(III) or FeSO4, hemoglobin concentrations and iron
stores in the mice were still suboptimal, and this was most
substantial in the spleen (Figure 2).
We previously reported, using chemical inhibitors, that nano
Fe(III) is taken up apically in Caco-2 cells by endocytosis followed
by pH- and ligand-driven breakdown in endosomes or lysosomes
within the cell (19). Although our data alluded to endocytosis as the
uptake mechanism, it remains unresolved as to whether the process
is by pinocytosis or by a receptor-mediated route that may resemble
that proposed for dietary ferritin uptake (38). The current study adds
further evidence for a distinct mechanism of cellular uptake of nano
Fe(III) compared to that of soluble iron. We used molecular
techniques, notably inhibition of DCYTB activity and Slc11a2
knockdown with siRNA, in preference to the less-specific pharma-
cologic inhibitors and have again shown that nano Fe(III) does not
require redox activity at themucosal surface of the cell before uptake
and that the uptake is independent of DMT1 (Figure 3). We believe
that an independent mechanism is now proven for the uptake of
nano Fe(III) by enterocytes because both approaches, namely
pharmacologic and molecular, lead to the same conclusions in vitro
[Figure 3 (19)] and are supported by chemical inhibition studies in
vivo (18). Of course, although the apical uptake of nano Fe(III)
might be independent of DMT1, the intracellular trafficking of Fe
derived from this compound, before basolateral export from the
enterocyte, may still involve vesicles containing internalized DMT1
just as is hypothesized for iron from soluble sources (39, 40). This
could be best investigated with use of the intestinal-specific DMT1-
knockout mouse model (41) and intracellular imaging of iron
because the formation of intracellular ferritin in cell culture, as
studied here, does not seem to require DMT-1.
Taken together, our data demonstrate that nano particulate
tartrate-modified Fe(III) poly oxo-hydroxide [i.e., nano Fe(III)]
is equally bioavailable to FeSO4 but that its apical cell uptake is
independent of DCYTB/DMT1-mediated import of soluble iron.
In our view, this distinct mechanism offers 2 main advantages: 1)
no requirement for reduction of Fe(III) at the mucosal surface
and, therefore, nano Fe(III) should have restricted luminal and
mucosal redox activity (and thus toxicity) (42, 43) while 2) nano
Fe(III) absorption is unlikely to be influenced by other divalent
metals present in the diet such as Zn or, indeed, vice versa (44–46).
Furthermore, any unabsorbed nano Fe(III) should have limited
redox activity in the distal colon because of the spatial arrange-
ment of the iron in the nanoparticle, which renders the gen-
eration of oxygen radicals less probable (47). Utilization by the
gut microbiota of iron from nano Fe(III) would also be more
challenging (48, 49).
Therefore, nano Fe(III) presents as a unique, safe, and bioavail-
able novel form of oral iron for use in the treatment of IDA.
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